- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00375427
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Forlì, Italien
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Female patients ≥ 18 years of age.
- Written informed consent given.
- Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.
- Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2 .
- Life expectancy ≥ 1 year.
Exclusion criteria:
- More than 3 months since last infusion of Zoledronic Acid (Zometa®).
- Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry.
- Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85
- Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).
- Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).
- Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).
- History of non-compliance to medical regimens or potential unreliable behavior.
- Known sensitivity to study drug(s) or class of study drug(s).
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Use of any other investigational agent in the last 30 days.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Every 3 months
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Randomized patients will receive a maximum of 4 infusions in this group.
|
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Andre navne:
|
Eksperimentel: Every 4 weeks
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Patients randomized to this group will receive up to 12 infusions.
|
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Annual Overall Skeletal Morbidity Rate (SMR)
Tidsramme: 12 months
|
The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio "days of observation period / 365.25", for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy. SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit. |
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)
Tidsramme: 12 month
|
Skeletal Related Events (SREs) are defined as a:
|
12 month
|
Annual Incidence of Any Skeletal Related Events (SREs)
Tidsramme: 12 months
|
Skeletal Related Events (SREs) are defined as a:
|
12 months
|
Median Time to First Skeletal Related Event(s) (SRE)
Tidsramme: 12 month
|
Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM).
Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability >=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.
|
12 month
|
Percentage of Participants Skeletal Related Event (SRE) Free
Tidsramme: 12 months
|
Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point. Skeletal Related Events (SREs) are:
|
12 months
|
Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire
Tidsramme: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire.
The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score.
The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study.
Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine).
The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value
Tidsramme: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment.
Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Use Of Analgesic Medications According to the Analgesic Score Scale
Tidsramme: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where: 0 = None
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score
Tidsramme: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
ECOG Performance Score has 4 grades.
0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities.
Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care.
Totally confined to bed/chair.
Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CZOL446EIT14
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Zoledronic acid
-
University of CalgaryRekrutteringSlidgigt i knæet | Forreste korsbåndsskader | Forreste korsbåndsruptur | Forreste korsbåndsrivningCanada
-
Institut Cancerologie de l'OuestRekruttering
-
Nantes University HospitalAfsluttetKæmpecelletumorer i knogleFrankrig
-
Affiliated Hospital of Hebei UniversityUkendtIkke-pladeeplade ikke-småcellet lungekræftKina
-
Ultragenyx Pharmaceutical IncAfsluttetHereditary Inclusion Body Myopati (HIBM)Forenede Stater
-
University of Colorado, DenverAfsluttetFedme | Polycystisk ovariesyndrom | Hepatisk SteatoseForenede Stater
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteAfsluttetBipolar depressionIrland
-
University of California, Los AngelesAfsluttetGlucoseintolerance | Overvægtige | Præ-diabetesForenede Stater
-
Ultragenyx Pharmaceutical IncAfsluttetArvelig Inclusion Body Myopati | GNE myopatiForenede Stater, Israel
-
Becton, Dickinson and CompanyAktiv, ikke rekrutterende